MedTrace Logo

Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN

NCT02630277 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-12-15

No results posted yet for this study

Summary

To assess the safety and efficacy of intravitreal aflibercept injection in the regression of retinal neovascularization secondary to high-risk PDR.

To characterize baseline/post-induction/maintenance levels of proinflammatory mediators in patients with high-risk PDR

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DRUG

Aflibercept

Intravitreal Aflibercept Injection 2.0 mg

Sponsors & Collaborators

  • Valley Retina Institute

    lead OTHER

Principal Investigators

  • Victor H Gonzalez, MD · Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-31
Completion
2017-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02630277 on ClinicalTrials.gov